Clinical trial NCT01841905: Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease
Official title: Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Alzheimer's Disease
Keywords: Alzheimer's Disease
Family History
Memory Concerns
Lead sponsor: Rhode Island Hospital
Sponsor class: OTHER
Collaborators: name: Pfizer
name: Heidelberg Engineering, Inc.
name: Neurotrack
name: Optovue
name: Avid Pharmaceuticals
First posted: 2013-04-29
Enrollment: 60
Sex: ALL
Minimum age (years): 55
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Individuals between the ages of 55 and 80 years old, and who have two risk factors for AD (subjective memory complaints as ascertained on a standardized questionnaire and a positive family history for the disease).

Brief summary: The investigators are conducting a study to try to improve our ability to identify older adults who are at high-risk for progression to Alzheimer's disease, several years before they have symptoms that might reduce their quality of life. The investigators believe they can increase the sensitivity of tests of memory and problem solving, by using a very small dose of a medication (scopolamine) that reduces the activity of the principal chemical system in the brain that is changing in the earliest stages of Alzheimer's disease. By pairing this "micro-dose" drug challenge (that is administered with a tiny needle placed just under the surface of the skin on the forearm), with our tests of memory and thinking, it is believed that the investigators can create a "stress test" that is very similar in concept to the use of the exercise treadmill to make the results of a heart EKG more sensitive to detect early disease, as a cardiac stress test for heart disease. The investigators want to create a similar stress test for Alzheimer's disease (AD).

Detailed description: We will take pictures of subjects' brains using PET imaging, in healthy older adults (ages 55 to 80 years) who have both a family history of AD, and who have concerns about changes in their memory (but no clinical symptoms of AD), to see how much of a protein - that is related to AD -is in their brains. When all subjects come to the hospital for PET imaging, we will review the entire study plan with them, the risks and benefits of participation, and we will obtain written informed consent at that time. Our goal is to compare performance on our new stress test to these PET imaging results. Once the PET imaging is done, we will have each subject come to our clinical research unit for a day-long baseline visit. In the morning we will give the tests of memory and thinking, and then we will administer the injection of scopolamine at a very low dose. We will then continue to examine the subjects, and to give the memory and thinking tests at 1, 3, 5, 7, and 8 hours post-dosing. Once they have fully-recovered from all effects of the medication, they will be allowed to go home that day. We will then see all subjects again, for much shorter visits to complete the cognitive tests, at both 9 and 18 months after their initial study visit. We will follow all subjects for 18 months to see which of them show very mild but measurable changes on the memory and thinking tests, as we predict that these will be the same persons who also had stronger results on our stress test at the first study visit.

At all three study visits to our clinical research unit, we will obtain measurements using an imaging device that uses infrared and blue light to take picture of the eye and retina. Our secondary goal in this study to search for evidence of the same protein, in the retina, that builds up and is seen with PET imaging of the brain in persons who are at high risk for AD. Finally, we are also collecting a small sample of saliva, at the first visit to our unit, in order to see which subjects have a genetic risk for the disease, as this genetic risk may affect how we interpret the results of our new "cognitive stress test".

In this study, a small dose of an already approved medication (used to treat seasickness) will be used to temporarily, and safely, mimic signs of very early disease during just the first day of testing. This is a methodological study to determine if tests that measure how you think can predict the risk of dementia as we age.

Eligibility criteria: Inclusion Criteria:

* Individuals between the ages of 55 and 80 years old (inclusive).
* MMSE total score \> 27
* Two risk factors for AD:
* Subjective memory complaints.
* A positive (suspected) first-degree family history for the disease.
* Permitted medications stable for at least 1 month prior to screening.
* Subjects may take stable doses of antidepressants lacking significant anticholinergic side effects (do not have a history of major depression within the past year).
* Estrogen replacement therapy.
* Adequate visual and auditory acuity to allow neuropsychological testing.
* Good general health or without any clinically significant abnormalities .
* Vitamin supplements (including Vitamin E) will be acceptable.
* Subjects must be willing and able to provide written informed consent.

Exclusion Criteria:

* History of major traumatic brain injury, other known neurologic disease or insult
* Mini Mental State Examination (MMSE)total score \< 27
* Regular (daily) use of narcotics or antipsychotic medications
* Poorly-controlled major depression or another Axis I psychiatric disorder as described in DSM-IV within the past year.
* Psychotic features, agitation or behavioral problems, within the last 3 months.
* History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).
* History of schizophrenia (DSM IV criteria).
* Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol including:
* History of systemic cancer within the past 5 years (non-metastatic skin cancers are acceptable).
* History of myocardial infarction in the past year or unstable or severe cardiovascular disease including angina or Congestive Heart Failure (CHF) with symptoms at rest.
* Clinically significant obstructive pulmonary disease or asthma.
* Clinically significant and unstable gastrointestinal disorder within two years.
* Insulin-requiring diabetes or uncontrolled diabetes mellitus.
* Uncontrolled hypertension (systolic BP \> 170 or diastolic BP \> 100).
* History of clinically significant liver disease, coagulopathy, or vitamin K deficiency within the past 2 years.
* History of symptoms of narrow-angle glaucoma.
* Clinically significant obstructive uropathy
* Use of centrally active beta-blockers, narcotics, methyldopa and clonidine within 4 weeks prior to screening.
* Use of anti-Parkinsonian medications (e.g., Sinemet, amantadine, bromocriptine, pergolide and selegiline) within 2 months prior to screening.
* Use of neuroleptics or narcotic analgesics within 4 weeks prior to screening.
* Use of long-acting benzodiazepines or barbiturates within 4 weeks prior to screen.
* Use of short-acting anxiolytics or sedative-hypnotics more frequently than 2 times per week within 4 weeks prior to screening (note: sedative agents should not be used within 72 hours of the baseline and follow-up visits.
* Initiation or change in dose of an antidepressant lacking significant cholinergic side effects within the 4 weeks prior to screening (use of stable doses of antidepressants for at least 4 weeks prior to screening is acceptable)
* Use of systemic corticosteroids within 3 months prior to screening.
* Medications with significant cholinergic or anticholinergic side effects within 4 weeks prior to screening.
* Use of anti-convulsants within 2 months prior to screening.
* Use of warfarin (Coumadin) within 4 weeks prior to screening.
* Any prior use of any FDA approved medications for the treatment of Alzheimer's disease (e.g., tacrine, donepezil, or other newly approved medications).
* Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening.
* Subjects who, in the investigator's opinion, will not comply with study procedures.
* Known hypersensitivity to F-18, tropicamide, and/or scopolamine or agents of this class of drugs.

Primary outcomes:
measure: Groton Maze Learning Test
timeFrame: 18 Months
Secondary outcomes:
measure: Groton Maze Learning Test
timeFrame: 18 Months
measure: CogState One-Back Learning (OBK) Task
timeFrame: 18 Months
measure: 12-Item International Shopping List Test - Immediate and Delayed Recall (CogState)
timeFrame: 18 Months
measure: Rentz Face-Name Association Test
timeFrame: 18 Months
measure: Stark Pattern Separation Test
timeFrame: 18 Months
measure: Minnesota Cognitive Acuity Scale (MCAS)
timeFrame: Pre-baseline
measure: Saliva Sample for DNA Analyses (ApoE and BDNF genotyping)
timeFrame: Baseline
measure: Non-invasive imaging of macula, retinal function and visual fields
timeFrame: 18 Months
measure: CogState Once-Card learning (OCL) Task
timeFrame: 18 Months
measure: Amyloid and Alzheimer's Psycho-educational Session
timeFrame: 9 and 18 month study visits
measure: Tokyo Subway Navigation
timeFrame: 9 month follow-up visit
measure: MAC-Q
timeFrame: Pre-screen, Baseline, 9 & 18 month follow-up
Other outcomes:
Locations:
city: Providence
country: United States
facility: Lifespan
state: Rhode Island
Study officials:
affiliation: Sr. Vice President & Chief Research Officer, Lifespan
name: Peter J. Snyder, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: